Relapsed/refractory DLBCL post ≥2 prior systemic therapies, NOT a candidate for anti-CD19...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-DLBCL-CART-INELIGIBLE-POST-2L |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-05-01 | pending_clinical_signoff |
| Diseases | DIS-DLBCL-NOS |
| Sources | SRC-ESMO-DLBCL-2024 SRC-NCCN-BCELL-2025 |
Red Flag Origin
| Definition | Relapsed/refractory DLBCL post ≥2 prior systemic therapies, NOT a candidate for anti-CD19 CAR-T (axi-cel / liso-cel / tisa-cel) due to frailty, organ dysfunction, comorbidity burden, manufacturing-window risk, prior CAR-T failure, or absent funded referral pathway. Routes 3L+ to loncastuximab tesirine (LOTIS-2 Caimi 2021 Lancet Oncol; ORR 48%, CR 24%, mPFS 4.9 mo, mOS 9.5 mo) — off-the-shelf outpatient ADC ideally suited for non-CAR-T-eligible frail patient. Distinct from universal RF-CAR-T-INELIGIBLE-AGE-COMORBID (which gates on age ≥75 + Charlson ≥4) — this flag covers the broader DLBCL-specific ineligibility composite including UA access constraints (no funded international referral pathway). |
|---|---|
| Clinical direction | intensify |
| Category | prior-therapy-class |
| Shifts algorithm | ALGO-DLBCL-2L |
Trigger Logic
{
"all_of": [
{
"any_of": [
{
"comparator": ">=",
"finding": "prior_lines_count",
"threshold": 2
},
{
"finding": "post_pola_failure",
"value": true
},
{
"finding": "primary_refractory",
"value": true
}
]
},
{
"any_of": [
{
"finding": "cart_ineligibility_reason"
},
{
"finding": "cart_ineligible",
"value": true
},
{
"all_of": [
{
"comparator": ">=",
"finding": "ecog",
"threshold": 2
},
{
"comparator": ">=",
"finding": "age",
"threshold": 70
}
]
},
{
"red_flag": "RF-CAR-T-INELIGIBLE-AGE-COMORBID"
},
{
"red_flag": "RF-CAR-T-INELIGIBLE-ORGAN"
}
]
}
],
"type": "composite_score"
}
Notes
Truthy lookup of `cart_ineligibility_reason` — if patient JSON sets this field to ANY explanatory string, the trigger fires. Provides flexibility for clinicians documenting case-specific rationale (e.g., "frailty_age_71_ECOG_2_no_international_referral_pathway", "prior_axicel_failure", "manufacturing_window_too_short_for_pd_kinetics"). Alternative composite path: explicit ECOG ≥2 + age ≥70 (frail older cohort) as observed in LOTIS-2 enrollment criteria. Universal CAR-T-ineligible RFs (age ≥75 + Charlson ≥4 OR organ dysfunction) are folded in via red_flag refs — this composite RF is the broader DLBCL-specific ineligibility signal.
Used By
Algorithms
ALGO-DLBCL-2L- ALGO-DLBCL-2LALGO-DLBCL-3L- ALGO-DLBCL-3L
Indications
IND-DLBCL-3L-EPCORITAMAB- IND-DLBCL-3L-EPCORITAMABIND-DLBCL-3L-GLOFITAMAB- IND-DLBCL-3L-GLOFITAMAB
Red flag
RF-DLBCL-CD20-POS-EPCORITAMAB-CANDIDATE- Relapsed/refractory DLBCL with confirmed CD20 expression on malignant B-cells, post ≥2 pr...RF-DLBCL-CD20-POS-GLOFITAMAB-CANDIDATE- Relapsed/refractory DLBCL with confirmed CD20 expression on malignant B-cells, post ≥2 pr...